<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Surg</journal-id><journal-id journal-id-type="iso-abbrev">Int J Surg</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">JS9</journal-id><journal-title-group><journal-title>International Journal of Surgery (London, England)</journal-title></journal-title-group><issn pub-type="ppub">1743-9191</issn><issn pub-type="epub">1743-9159</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430794</article-id><article-id pub-id-type="pmcid-ver">PMC12430794.1</article-id><article-id pub-id-type="pmcaid">12430794</article-id><article-id pub-id-type="pmcaiid">12430794</article-id><article-id pub-id-type="pmid">40474830</article-id><article-id pub-id-type="doi">10.1097/JS9.0000000000002653</article-id><article-id pub-id-type="publisher-id">IJS-D-25-02486</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Letter to the Editor: a commentary on &#8220;Surgical treatment of synchronous liver-only oligometastatic pancreatic adenocarcinoma: a systematic review and meta-analysis of long-term outcomes&#8221;</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="P">Pei</given-names></name><degrees>MD</degrees><email>305827337@qq.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cai</surname><given-names initials="X">Xianfu</given-names></name><degrees>MD</degrees><email>caixianfu@126.com</email><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zeng</surname><given-names initials="X">Xintao</given-names></name><degrees>MM</degrees><email>zengxintao@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Luo</surname><given-names initials="H">Huiwen</given-names></name><degrees>MD</degrees><email>18280016646@163.com</email><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="J">Jianjun</given-names></name><degrees>MD</degrees><email>wangjianjunmch@163.com</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Department of Hepatobiliary Surgery, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China</aff><aff id="aff2"><label>b</label>Department of Urology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China</aff><aff id="aff3"><label>c</label>NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China</aff></contrib-group><author-notes><corresp id="COR0001"><label>*</label>Corresponding author. Address: NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang 621000, China. E-mail: <email>18280016646@163.com</email>. Tel.: +86 17364033760 (H. Luo); Department of Hepatobiliary Surgery, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang 621000, China. E-mail: <email>wangjianjunmch@163.com</email>. Tel.: +86 13698128650 (J. Wang).</corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>05</day><month>6</month><year>2025</year></pub-date><volume>111</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496813</issue-id><fpage>6505</fpage><lpage>6507</lpage><history><date date-type="received"><day>21</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0</ext-link> (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="js9-111-6505.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="js9-111-6505.pdf"/><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><italic toggle="yes">Dear Editor</italic>,</p><p>Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors worldwide, currently ranking as the fourth leading cause of cancer-related death, and it is expected to rise to second place by 2030<sup>[<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>]</sup>. Despite the ongoing development of multimodal treatment strategies, including neoadjuvant chemotherapy, precision staging, and adjuvant therapy, the overall survival rate for PDAC remains extremely low, with a 5-year survival rate of less than 10%<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup>. Approximately 20% of patients are eligible for curative resection at the time of diagnosis, while 50%&#8211;60% present with distant metastases, with liver metastasis being the most common<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup>. For PDAC patients with synchronous liver metastasis, systemic chemotherapy remains the standard treatment, with first-line regimens including FOLFIRINOX or Gemcitabine combined with nab-Paclitaxel<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup>.</p><p>Recently, with the growing understanding of the biological characteristics of oligometastatic disease, some studies have started exploring the potential role of local interventions (including surgery or ablation) in oligometastatic solid tumors, yielding positive results in colorectal cancer, breast cancer, and other malignancies<sup>[<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>]</sup>. However, in the case of PDAC, a highly aggressive cancer, the effectiveness of surgical interventions in improving the prognosis of patients with synchronous oligometastasis remains controversial, and high-quality evidence to support this approach is still lacking.</p><p>In this context, the study by Fiorillo <italic toggle="yes">et al</italic><sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> provides preliminary evidence on the long-term survival benefits of combined resection of both the primary tumor and metastatic lesions in PDAC patients with synchronous liver oligometastasis. This study is of significant exploratory value; however, from the perspective of surgical oncology and evidence-based medicine, several key issues warrant further investigation.</p><sec><title>Inconsistent definitions of oligometastasis and insufficient heterogeneity control</title><p>The definition of &#8220;oligometastasis&#8221; in the 11 studies included in the analysis is not uniform. Some studies did not specify the number of metastatic lesions, and some included cases with as many as 21 liver metastases, which deviates significantly from current research consensus. Recent studies have recommended defining PDAC oligometastasis as having &#8804;3 liver metastatic lesions to improve comparability and research interpretability<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup>. However, this study did not perform subgroup analysis or sensitivity validation for this variable, which may lead to a lack of stability in the overall conclusions.</p></sec><sec><title>Lack of clarity in systemic treatment regimens in the non-surgical group</title><p>In this study, all non-surgical patients were classified as receiving &#8220;systemic chemotherapy,&#8221; but only a few studies specified the chemotherapy regimens. According to guidelines, there are significant differences in both efficacy and side effects between FOLFIRINOX and Gemcitabine&#160;+&#160;nab-Paclitaxel<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup>. The lack of stratification based on chemotherapy regimens may introduce bias due to unequal treatment intensities, undermining the basis for comparing the effectiveness of surgical treatments.</p></sec><sec><title>Retrospective nature of the studies and lower evidence level</title><p>All the studies included in this analysis were retrospective cohort studies, with no prospective or randomized controlled trials included. Furthermore, most studies did not perform propensity score matching, which exposes them to high risks of selection bias and confounding factors. Although the quality of the included studies was assessed using the Newcastle&#8211;Ottawa Scale, the methodological limitations of this approach mean that the evidence derived from this meta-analysis should be interpreted with caution. We believe future research should focus on multicenter, prospective trials, or large-scale real-world cohort studies to strengthen the evidence base in this field.</p></sec><sec><title>Vascular invasion not systematically included in the analysis</title><p>Vascular invasion, particularly of key vessels such as the portal vein, superior mesenteric vein, or artery, is a critical factor in determining resectability and postoperative prognosis in PDAC. Recent guidelines have included vascular invasion as a key standard for &#8220;borderline resectability&#8221; and &#8220;neoadjuvant treatment recommendation&#8221;<sup>[<xref rid="R9" ref-type="bibr">9</xref>&#8211;<xref rid="R11" ref-type="bibr">11</xref>]</sup>. Although some original studies mentioned the rate of vascular resection, the authors did not systematically extract data on vascular invasion nor assess its impact on perioperative complications or long-term survival. We suggest that future studies incorporate this variable into predefined subgroup analyses.</p></sec><sec><title>Heterogeneity of tumor location and surgical approach not addressed</title><p>Different anatomical locations of PDAC necessitate different surgical approaches, which can significantly impact postoperative complications and the timing of adjuvant treatments. For example, tumors in the head of the pancreas typically require pancreaticoduodenectomy, which is associated with a higher risk of complications, including anastomotic leaks, compared to distal pancreatectomy. Although the authors mention surgical approaches in the supplementary tables, the main analysis did not explore the relationship between surgical approach and the incidence of severe complications (e.g. Clavien-Dindo &#8805;3). We recommend that surgical approach and tumor location be incorporated as subgroup variables in future analyses.</p></sec><sec><title>Preoperative biological response should be a basis for surgical indication</title><p>We fully agree with the authors&#8217; discussion regarding the potential predictive value of preoperative CA19-9 decline and radiological response in identifying patients who may benefit from surgery. Previous studies have shown that such &#8220;biological conversion markers&#8221; are closely related to long-term survival outcomes in PDAC patients<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>]</sup>. We suggest that preoperative biological response should be incorporated into decision-making models to better define the subgroup of patients who would truly benefit from surgery.</p><p>In conclusion, Fiorillo <italic toggle="yes">et al</italic>&#8217;s<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> study provides preliminary evidence for the surgical treatment of PDAC patients with synchronous liver oligometastasis and offers important exploratory insights. We recommend that future studies be prospective, multicenter, and rigorously standardized, particularly in developing individualized surgical decision models based on tumor burden, biological behavior, and multidisciplinary evaluations, to optimize the comprehensive treatment strategies for this high-risk patient population<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup>.</p></sec></body><back><fn-group><fn fn-type="other"><p>P.Y., X.C., and X.Z. have contributed equally to this work.</p></fn><fn fn-type="other"><p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p></fn><fn fn-type="equal"><p>Published online 5 June 2025</p></fn></fn-group><sec><title>Ethical approval</title><p>This correspondence did not require ethical approval.</p></sec><sec><title>Consent</title><p>Not applicable.</p></sec><sec><title>Source of funding</title><p>This work did not receive any funding related to its research, authorship, or publication.</p></sec><sec><title>Author contributions</title><p>P.Y., X.C., and X.Z. found the question and wrote the draft. H.L. and J.W. revised the manuscript. P.Y., X.C., and X.Z. contributed equally to this work and shared the first authorship. H.L. and J.W. contributed equally to this work and shared corresponding authorship. All authors have approved the letter.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest disclosure</title><p>The authors declare that they have no competing interests related to this work.</p></sec><sec><title>Research registration unique identifying number (UIN)</title><p>Not applicable.</p></sec><sec><title>Guarantor</title><p>Jianjun Wang.</p></sec><sec><title>Provenance and peer review</title><p>This paper was not invited.</p></sec><sec sec-type="data-availability"><title>Data availability statement</title><p>All data analyzed or generated during this study are included in the article.</p></sec><sec><title>Declaration and use of AI</title><p>No artificial intelligence tools were used in the design, execution, or writing of this study and our article is compliant with the TITAN Guidelines 2025.</p></sec><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michl</surname><given-names>P</given-names></name><name name-style="western"><surname>L&#246;hr</surname><given-names>M</given-names></name><name name-style="western"><surname>Neoptolemos</surname><given-names>JP</given-names></name><etal/></person-group>. <article-title>UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: prevent, detect, and treat the disease earlier and better</article-title>. <source>United Eur Gastroenterol J</source><year>2021</year>;<volume>9</volume>:<fpage>860</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ueg2.12123</pub-id><pub-id pub-id-type="pmcid">PMC8435257</pub-id><pub-id pub-id-type="pmid">34431604</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahib</surname><given-names>L</given-names></name><name name-style="western"><surname>Smith</surname><given-names>BD</given-names></name><name name-style="western"><surname>Aizenberg</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States</article-title>. <source>Cancer Res</source><year>2014</year>;<volume>74</volume>:<fpage>2913</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">24840647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-14-0155</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="webpage"><collab>Fact SCS</collab>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://seer.cancer.gov/statfacts/html/pancreas.html" ext-link-type="uri">https://seer.cancer.gov/statfacts/html/pancreas.html</ext-link></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moyer</surname><given-names>MT</given-names></name><name name-style="western"><surname>Gaffney</surname><given-names>RR</given-names></name></person-group>. <article-title>Pancreatic adenocarcinoma</article-title>. <source>N Engl J Med</source><year>2014</year>;<volume>371</volume>:<fpage>2140</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc1412266</pub-id><pub-id pub-id-type="pmid">25427125</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conroy</surname><given-names>T</given-names></name><name name-style="western"><surname>Pfeiffer</surname><given-names>P</given-names></name><name name-style="western"><surname>Vilgrain</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up</article-title>. <source>Ann Oncol</source><year>2023</year>;<volume>34</volume>:<fpage>987</fpage>&#8211;<lpage>1002</lpage>.<pub-id pub-id-type="pmid">37678671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2023.08.009</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carconi</surname><given-names>C</given-names></name><name name-style="western"><surname>Cerreti</surname><given-names>M</given-names></name><name name-style="western"><surname>Roberto</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The management of oligometastatic disease in colorectal cancer: present strategies and future perspectives</article-title>. <source>Crit Rev Oncol Hematol</source><year>2023</year>;<volume>186</volume>:<fpage>103990</fpage>.<pub-id pub-id-type="pmid">37061075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2023.103990</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nesbit</surname><given-names>EG</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>ED</given-names></name><name name-style="western"><surname>Strauss</surname><given-names>JB</given-names></name></person-group>. <article-title>Treatment strategies for oligometastatic breast cancer</article-title>. <source>Curr Treat Options Oncol</source><year>2021</year>;<volume>22</volume>:<fpage>94</fpage>.<pub-id pub-id-type="pmid">34426881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11864-021-00889-2</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiorillo</surname><given-names>C</given-names></name><name name-style="western"><surname>Langellotti</surname><given-names>L</given-names></name><name name-style="western"><surname>Panza</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Surgical treatment of synchronous liver-only oligometastatic pancreatic adenocarcinoma: a systematic review and meta-analysis of long-term outcomes</article-title>. <source>Int J Surg</source><year>2025</year>;<volume>111</volume>:<fpage>3589</fpage>&#8211;<lpage>98</lpage>.<pub-id pub-id-type="pmid">40101129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JS9.0000000000002338</pub-id><pub-id pub-id-type="pmcid">PMC12165493</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoop</surname><given-names>TF</given-names></name><name name-style="western"><surname>Javed</surname><given-names>AA</given-names></name><name name-style="western"><surname>Oba</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Pancreatic cancer</article-title>. <source>Lancet</source><year>2025</year>;<volume>405</volume>.<fpage>1182</fpage>&#8211;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(25)00261-2</pub-id>. <comment>Erratum in: Lancet. 2025 17;405(10491):1742. doi: 10.1016/S0140-6736(25)00992-4</comment><pub-id pub-id-type="pmid">40187844</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Narang</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Consensus, debate, and prospective on pancreatic cancer treatments</article-title>. <source>J Hematol Oncol</source><year>2024</year>;<volume>17</volume>:<fpage>92</fpage>.<pub-id pub-id-type="pmid">39390609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-024-01613-x</pub-id><pub-id pub-id-type="pmcid">PMC11468220</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoop</surname><given-names>TF</given-names></name><name name-style="western"><surname>Theijse</surname><given-names>RT</given-names></name><name name-style="western"><surname>Seelen</surname><given-names>LWF</given-names></name><etal/></person-group>. <article-title>Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer</article-title>. <source>Nat Rev Gastroenterol Hepatol</source><year>2024</year>;<volume>21</volume>:<fpage>101</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">38036745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41575-023-00856-2</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agha</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>G</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Transparency in the reporting of Artificial INtelligence &#8211; the TITAN guideline</article-title>. <source>Prem J Sci</source><year>2025</year>;<volume>10</volume>:<fpage>100082</fpage>.</mixed-citation></ref></ref-list></back></article></pmc-articleset>